Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basmisanil for GABAA receptor occupancy in healthy Japanese volunteers
NCT02534207Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of basmisanil in intellectual disability (ID) and cognitive impairment, sponsored by Roche. Primary endpoints: Percentage of Brain α5 Subunit-Containing GABAA Receptors Occupied by Basmisanil in Selected Regions of Interest (ROIs) Assessed by PET Imaging at Day 1 and Correlation Between Basmisanil Plasma Concentration and Occupancy of Brain α5 Subunit-Containing GABAA Receptors at Day 1. Started Aug 2015; status: completed.
02
Drugs
basmisanil
03
Conditions
intellectual disability (ID)cognitive impairment
Beyond the preview
Go deeper on NCT02534207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534207.